Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study.

MLA

Ueshima, Kazuomi, et al. “Primary Analysis of a Phase II Study of Atezolizumab plus Bevacizumab for TACE-Unsuitable Patients with Tumor Burden beyond up-to-Seven Criteria in Intermediate-Stage Hepatocellular Carcinoma: REPLACEMENT Study.” Journal of Clinical Oncology, vol. 41, June 2023, p. 4125. EBSCOhost, https://doi.org/10.1200/JCO.2023.41.16_suppl.4125.

APA

Ueshima, K., Kudo, M., Tsuchiya, K., Kato, N., Yamashita, T., Shimose, S., Numata, K., Kodama, Y., Tanaka, Y., Kuroda, H., Itoh, S., Aikata, H., Hiraoka, A., Moriguchi, M., Wada, Y., Nakao, K., Tateishi, R., Ogasawara, S., Yamamoto, K., & Ikeda, M. (2023). Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study. Journal of Clinical Oncology, 41, 4125. https://doi.org/10.1200/JCO.2023.41.16_suppl.4125

Chicago

Ueshima, Kazuomi, Masatoshi Kudo, Kaoru Tsuchiya, Naoya Kato, Tatsuya Yamashita, Shigeo Shimose, Kazushi Numata, et al. 2023. “Primary Analysis of a Phase II Study of Atezolizumab plus Bevacizumab for TACE-Unsuitable Patients with Tumor Burden beyond up-to-Seven Criteria in Intermediate-Stage Hepatocellular Carcinoma: REPLACEMENT Study.” Journal of Clinical Oncology 41 (June): 4125. doi:10.1200/JCO.2023.41.16_suppl.4125.